| 2019 |
| 02/28 | 15:00 米国の主要ながん研究施設Fox Chase Cancer Centerとの合弁会社への出資に関するお知らせ |
| 02/25 | 254 | 271 | 252 | 268 | +6.77% | 1,655,800 | 190億4579万 | +18.06% |
| 02/22 | 262 | 264 | 250 | 251 | -4.2% | 1,513,700 | 178億3766万 | +11.06% |
| 02/21 | 247 | 264 | 246 | 262 | +9.62% | 3,831,200 | 186億1939万 | +16.44% |
| 02/20 | 246 | 251 | 238 | 239 | -3.63% | 1,975,000 | 169億8486万 | +6.7% |
| 02/19 | 245 | 284 | 244 | 248 | +8.77% | 16,408,000 | 176億2446万 | +11.21% |
| 02/18 | 220 | 230 | 219 | 228 | +4.59% | 684,000 | 162億313万 | +2.7% |
| 02/15 | 216 | 222 | 213 | 218 | +0.93% | 375,000 | 154億9247万 | -1.36% |
| 02/14 | 231 | 231 | 215 | 216 | -4% | 662,500 | 153億5034万 | -2.26% |
| 02/13 | 15:00 営業外収益の計上に関するお知らせ |
| 02/13 | 15:00 2019年3月期第3四半期決算短信〔日本基準〕(連結) |
| 02/13 | 220 | 227 | 218 | 225 | +1.81% | 361,700 | 159億8993万 | +1.81% |
| 02/12 | 217 | 221 | 216 | 221 | +4.25% | 323,600 | 157億567万 | +0.45% |
| 02/08 | 215 | 217 | 210 | 212 | -1.85% | 401,400 | 150億6607万 | -3.2% |
| 02/07 | 222 | 223 | 215 | 216 | -2.26% | 411,900 | 153億5034万 | -1.37% |
| 02/06 | 223 | 225 | 220 | 221 | 0% | 257,700 | 157億567万 | +1.38% |
| 02/05 | 225 | 228 | 220 | 221 | +1.84% | 580,100 | 157億567万 | +2.31% |
| 02/04 | 15:00 瑞太生物技術（上海）有限会社との中国における販売業務提携のお知らせ |
| 02/04 | 214 | 222 | 214 | 217 | 0% | 357,500 | 154億2140万 | +1.4% |
| 02/01 | 218 | 218 | 212 | 217 | +1.4% | 300,400 | 154億2140万 | +1.88% |
| 01/31 | 216 | 217 | 213 | 214 | +2.39% | 290,700 | 152億820万 | +0.94% |
| 01/30 | 220 | 221 | 208 | 209 | -6.28% | 689,200 | 148億5287万 | -1.42% |
| 01/29 | 223 | 224 | 218 | 223 | -0.45% | 299,700 | 158億4780万 | +5.19% |
| 01/28 | 234 | 234 | 223 | 224 | -3.03% | 362,200 | 159億1887万 | +5.66% |
| 01/25 | 230 | 234 | 228 | 231 | 0% | 389,500 | 164億1633万 | +8.96% |
| 01/24 | 223 | 232 | 222 | 231 | +3.13% | 291,500 | 164億1633万 | +8.96% |
| 01/23 | 218 | 226 | 218 | 224 | +0.45% | 342,100 | 159億1887万 | +5.66% |
| 01/22 | 222 | 227 | 217 | 223 | 0% | 497,600 | 158億4780万 | +5.19% |
| 01/21 | 15:00 分担企業として参加するAMED公募事業の平成29年度補助金交付額確定に関するお知らせ |
| 01/21 | 238 | 239 | 223 | 223 | -5.51% | 788,800 | 158億4780万 | +4.69% |
| 01/18 | 231 | 237 | 229 | 236 | +1.72% | 524,900 | 167億7166万 | +10.8% |
| 01/17 | 225 | 233 | 224 | 232 | +4.04% | 1,075,600 | 164億8740万 | +8.92% |
| 01/16 | 218 | 227 | 217 | 223 | +2.29% | 570,800 | 158億4780万 | +4.21% |
| 01/15 | 214 | 222 | 211 | 218 | +0.46% | 587,400 | 154億9247万 | +0.93% |
| 01/11 | 220 | 221 | 214 | 217 | 0% | 523,800 | 154億2140万 | -0.46% |
| 01/10 | 208 | 217 | 207 | 217 | +2.36% | 775,300 | 154億2140万 | -1.36% |
| 01/09 | 218 | 222 | 209 | 212 | -1.85% | 801,900 | 150億6607万 | -4.07% |
| 01/08 | 209 | 218 | 209 | 216 | +4.35% | 706,900 | 153億5034万 | -3.14% |
| 01/07 | 210 | 212 | 204 | 207 | +3.5% | 763,400 | 147億1074万 | -7.59% |
| 01/04 | 186 | 201 | 186 | 200 | +4.71% | 709,100 | 142億1327万 | -11.5% |
| 2018 |
| 12/28 | 186 | 192 | 186 | 191 | 0% | 592,100 | 135億7368万 | -15.86% |
| 12/27 | 189 | 193 | 186 | 191 | +4.95% | 891,400 | 135億7368万 | -16.59% |
| 12/26 | 180 | 186 | 177 | 182 | +6.43% | 950,900 | 129億3408万 | -21.21% |
| 12/25 | 16:20 再生医療製品ステムカイマルの希少疾病用再生医療等製品への指定 |
| 12/25 | 170 | 179 | 170 | 171 | -10% | 2,306,000 | 121億5235万 | -26.92% |
| 12/21 | 192 | 197 | 186 | 190 | -3.55% | 1,413,400 | 135億261万 | -19.83% |
| 12/20 | 209 | 210 | 195 | 197 | -6.19% | 1,313,300 | 140億7万 | -17.23% |
| 12/19 | 210 | 217 | 209 | 210 | -0.47% | 639,400 | 149億2394万 | -12.13% |
| 12/18 | 212 | 217 | 211 | 211 | -3.65% | 651,300 | 149億9500万 | -12.08% |
| 12/17 | 225 | 226 | 217 | 219 | -4.37% | 663,300 | 155億6353万 | -9.13% |
| 12/14 | 235 | 238 | 229 | 229 | -3.38% | 393,200 | 162億7420万 | -4.98% |
| 12/13 | 242 | 242 | 233 | 237 | +1.28% | 555,500 | 168億4273万 | -1.66% |
| 12/12 | 225 | 235 | 224 | 234 | +4.93% | 686,000 | 166億2953万 | -2.9% |
| 12/11 | 232 | 237 | 222 | 223 | -2.62% | 931,300 | 158億4780万 | -7.08% |
| 12/10 | 238 | 238 | 228 | 229 | -3.78% | 664,400 | 162億7420万 | -4.58% |
| 12/07 | 246 | 249 | 238 | 238 | -1.24% | 565,500 | 169億1380万 | -0.42% |
| 12/06 | 256 | 258 | 235 | 241 | -6.59% | 1,259,000 | 171億2700万 | +1.26% |
| 12/05 | 253 | 258 | 252 | 258 | +0.39% | 596,000 | 183億3512万 | +8.86% |
| 12/04 | 264 | 266 | 256 | 257 | -3.02% | 902,700 | 182億6406万 | +9.36% |
| 12/03 | 268 | 270 | 262 | 265 | +0.38% | 927,900 | 188億3259万 | +14.22% |
| 11/30 | 252 | 267 | 252 | 264 | +3.13% | 1,029,900 | 187億6152万 | +14.78% |
| 11/29 | 264 | 264 | 254 | 256 | -0.39% | 852,500 | 181億9299万 | +12.28% |
| 11/28 | 248 | 262 | 244 | 257 | +5.76% | 1,460,800 | 182億6406万 | +13.22% |
| 11/27 | 12:00 湘南ヘルスイノベーションパークへの入居のお知らせ |
| 11/27 | 248 | 254 | 243 | 243 | -3.57% | 1,135,100 | 172億6913万 | +8% |
| 11/26 | 12:00 再生医療製品ステムカイマルの希少疾病用再生医療等製品の指定の了承について |
| 11/26 | 235 | 279 | 234 | 252 | +6.33% | 7,838,500 | 179億873万 | +12% |
| 11/22 | 239 | 241 | 234 | 237 | -0.84% | 477,400 | 168億4273万 | +5.33% |
| 11/21 | 231 | 240 | 231 | 239 | +0.84% | 558,700 | 169億8486万 | +6.22% |
| 11/20 | 243 | 246 | 237 | 237 | -4.05% | 684,600 | 168億4273万 | +5.33% |
| 11/19 | 242 | 251 | 234 | 247 | +1.65% | 1,380,700 | 175億5339万 | +9.78% |
| 11/16 | 229 | 247 | 229 | 243 | +6.58% | 1,526,400 | 172億6913万 | +8% |
| 11/15 | 230 | 234 | 226 | 228 | -2.15% | 610,900 | 162億313万 | +1.33% |
| 11/14 | 230 | 237 | 228 | 233 | +2.64% | 568,600 | 165億5846万 | +3.56% |
| 11/13 | 15:00 2019年3月期第2四半期決算短信〔日本基準〕(連結) |
| 11/13 | 15:00 営業外収益及び営業外費用の計上に関するお知らせ |
| 11/13 | 224 | 230 | 220 | 227 | -2.58% | 623,100 | 161億3207万 | +0.89% |
| 11/12 | 232 | 242 | 230 | 233 | +1.3% | 1,124,900 | 165億5846万 | +3.56% |
| 11/09 | 222 | 245 | 222 | 230 | +2.68% | 1,622,200 | 163億4526万 | +2.22% |
| 11/08 | 224 | 229 | 222 | 224 | +1.82% | 367,100 | 159億1887万 | -0.88% |
| 11/07 | 218 | 225 | 216 | 220 | +0.46% | 579,400 | 156億3460万 | -2.65% |
| 11/06 | 220 | 223 | 214 | 219 | +0.46% | 375,200 | 155億6353万 | -3.95% |
| 11/05 | 216 | 223 | 211 | 218 | +1.87% | 496,700 | 154億9247万 | -4.8% |
| 11/02 | 206 | 215 | 206 | 214 | +3.88% | 490,600 | 152億820万 | -6.96% |
| 11/01 | 209 | 211 | 204 | 206 | -2.83% | 321,700 | 146億3967万 | -10.82% |
| 10/31 | 207 | 213 | 206 | 212 | +4.43% | 599,600 | 150億6607万 | -9.01% |
| 10/30 | 195 | 207 | 195 | 203 | +2.01% | 763,400 | 144億2647万 | -13.62% |
| 10/29 | 206 | 211 | 198 | 199 | -2.93% | 920,800 | 141億4221万 | -15.68% |
| 10/26 | 214 | 216 | 201 | 205 | -2.38% | 1,121,300 | 145億6861万 | -13.87% |
| 10/25 | 219 | 219 | 210 | 210 | -7.49% | 1,147,700 | 149億2394万 | -11.76% |
| 10/24 | 231 | 235 | 226 | 227 | -0.44% | 607,200 | 161億3207万 | -5.02% |
| 10/23 | 236 | 239 | 227 | 228 | -4.2% | 817,500 | 162億313万 | -4.6% |
| 10/22 | 237 | 239 | 232 | 238 | +0.42% | 325,400 | 169億1380万 | 0% |
| 10/19 | 241 | 245 | 235 | 237 | -3.27% | 686,200 | 168億4273万 | -0.42% |
| 10/18 | 244 | 250 | 244 | 245 | +0.82% | 688,100 | 174億1126万 | +3.38% |
| 10/17 | 249 | 249 | 242 | 243 | -1.22% | 655,900 | 172億6913万 | +2.97% |
| 10/16 | 231 | 249 | 231 | 246 | +5.58% | 1,018,500 | 174億8233万 | +4.24% |
| 10/15 | 236 | 237 | 230 | 233 | -1.27% | 530,900 | 165億5846万 | -0.85% |
| 10/12 | 227 | 238 | 227 | 236 | +3.06% | 664,800 | 167億7166万 | 0% |
| 10/11 | 222 | 232 | 221 | 229 | -5.76% | 1,179,800 | 162億7420万 | -2.97% |
| 10/10 | 240 | 247 | 238 | 243 | +5.65% | 1,519,800 | 172億6913万 | +2.53% |
| 10/09 | 15:00 次世代CRISPR Cas9技術「SNIPER」を活用したiPS細胞ゲノム編集サービス開始のお知らせ |
| 10/09 | 10:00 株式会社ファンケルとの共同開発製品ヒトiPS細胞由来の感覚神経細胞の受託製造サービス開始に関するお知らせ |
| 10/09 | 246 | 262 | 229 | 230 | -3.36% | 5,496,500 | 163億4526万 | -2.13% |
| 10/05 | 235 | 245 | 235 | 238 | -0.42% | 533,500 | 169億1380万 | +1.28% |
| 10/04 | 243 | 244 | 236 | 239 | -2.05% | 367,800 | 169億8486万 | +2.14% |
| 10/03 | 247 | 249 | 238 | 244 | -2.4% | 658,300 | 173億4019万 | +5.17% |
| 10/02 | 258 | 259 | 247 | 250 | +0.81% | 1,002,800 | 177億6659万 | +8.23% |
| 10/01 | 246 | 251 | 243 | 248 | +1.22% | 497,200 | 176億2446万 | +8.3% |
| 09/28 | 251 | 253 | 242 | 245 | -2% | 762,100 | 174億1126万 | +7.93% |
| 09/27 | 255 | 256 | 247 | 250 | -3.47% | 1,171,500 | 177億6659万 | +11.11% |
| 09/26 | 253 | 264 | 253 | 259 | +0.78% | 1,590,900 | 184億619万 | +16.14% |
